| Tevimbra (tislelizumab-jsgr) / BeiGene |
ChiCTR2000032825: Clinical trial of Ondo combined with DP combined with tirelizumab in the treatment of stage IIIB-IV lung squamous cell carcinoma |
|
|
| Recruiting | 4 | 25 | China | Four-drug combination therapy: patients were treated with endor, Tislelizumab, Docetaxel, and CISPLATIN. | Xinjiang Medical University Affiliated Oncology Hospital ; Xinjiang Medical University Affiliated Oncology Hospital, Funded by Beigene Shenzhou (Beijing) Biopharmaceutical Technology Co., Ltd | Squamous cell carcinomas | | | | |
ChiCTR2000033239: Study for the Efficacy and Safety of Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy |
|
|
| Not yet recruiting | 4 | 77 | China | Tislelizumab (Anti-PD1 Antibody) Combined With chemotherapy | Zhejiang Jinhua Guangfu Tumor Hospital ; None, Beigene | Non small cell lung cancer | | | | |
ChiCTR2000033177: The real world study of tislilizumab in the treatment of locally advanced or metastatic urothelial carcinoma |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab, IV, 200mg, Q3w | Department of Urology, the First Affiliated Hospital of Chongqing Medical University ; The First Affiliated Hospital of Chongqing Medical University, BeiGene (Beijing) Biotechnology Co., Ltd. | Urothelial carcinoma | | | | |
ChiCTR2000040095: Exploratory clinical study of chemotherapy combined with Immune checkpoint inhibitors for locally advanced and distant metastatic penile cancer |
|
|
| Not yet recruiting | 4 | 15 | China | Albumin taxol + Cisplatin + Bleomycin+Tislelizumab Injection | Beijing Chaoyang Huanxing Cancer Hospital ; Beijing Chaoyang Huanxing Cancer Hospital, Beijing Medical Award Foundation, Baiji Shenzhou (Beijing) Biotechnology Co., LTD | Penile cancer | | | | |
ChiCTR2000033441: Tislelizumab plus Gemox in relapsed or refractory patients with cHL |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab plus Gemox | Anhui Provincial Cancer Hospital ; Anhui Provincial Cance Hospital, Self-collected | cHL | | | | |
ChiCTR2000039620: Single-arm, single-center exploratory clinical study of terelizumab injection combined with Antinib hydrochloride capsule in the treatment of unresectable hepatocellular carcinoma |
|
|
| Recruiting | 4 | 30 | China | Tirelizumab injection combined with antinib hydrochloride capsule | The First Affiliated Hospital of Guangxi Medical University ; The First Affiliated Hospital of Guangxi Medical University, Baiji Shenzhou (Beijing) Biological Technology Co. Ltd; Chia Tai Tianqing Pharmaceutical Group Co. Ltd. | Cancer of the liver | | | | |
ChiCTR2000033599: PD-1 monoclonal antibody (tirelizumab) alternative radiotherapy for children with classic Hodgkin's lymphoma: a prospective, one-arm, open-label real-world study |
|
|
| Recruiting | 4 | 40 | China | Intravenous Tislelizumab | Beijing Boren Hospital ; Beijing Boren Hospital, Self-raised | Children's classic Hodgkin's lymphoma | | | | |
ChiCTR2100049944: Tislelizumab plus Gemox in relapsed or refractory patients with ENKTCL |
|
|
| Not yet recruiting | 4 | 30 | China | Tislelizumab in combination with gemcitabine and oxaliplatin | Jiangsu Provincial People's Hospital ; Jiangsu Provincial People's Hospital, Self-collected | ENKTCL | | | | |
TINES, NCT05603065: Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 4 | 32 | RoW | Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy | First Affiliated Hospital Xi'an Jiaotong University | Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
ChiCTR2200056941: Neoadjuvant treatment with Tislelizumab combined with GP regimen for high-risk (T4/N3) locally advanced nasopharyngeal carcinoma：an open-lable clinicaltrial |
|
|
| Not yet recruiting | 4 | 25 | China | Tislelizumab combine with GP regimen | Jiangmen Central Hospital ; Jiangmen Central Hospital, Self financing | Nasopharyngeal carcinoma | | | | |
ChiCTR2100047036: A single-arm, single-center, prospective real-world study of Tislelizumab in the treatment of patients with advanced metastatic or unresectable renal clear cell carcinoma |
|
|
| Recruiting | 4 | 45 | | Nil | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, BeiGene (Beijing) Biotechnology Co., Ltd. | Advanced renal clear cell carcinoma | | | | |
ChiCTR2200056181: Single-arm and exploratory clinical study of lenvatinib, tirelizumab and radiotherapy combined with HAIC in the treatment of hepatocellular carcinoma with portal vein tumor thrombus |
|
|
| Recruiting | 4 | 38 | China | Lenvatinib+Tislelizumab+Radiotherapy + Hepatic Artery Infusion Chemotherapy (HAIC) | Zhongshan Hospital Xiamen University ; Zhongshan Hospital Xiamen University, self-funded | Hepatocellular carcinoma | | | | |
PILOT, NCT06357598: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer |
|
|
| Recruiting | 4 | 30 | RoW | Tislelizumab, PD-1 antibody, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), chemotherapeutic drug, Carboplatin or Cisplatin, Surgery | The Affiliated Hospital of Qingdao University | Non-small-cell Lung Cancer (NSCLC) | 12/24 | 12/25 | | |
ChiCTR2000037670: A Multicenter Study of Neoadjuvant Tislelizumab (BGB-A317, anti-PD-1 antibody) combined with Cisplatin and Gemcitabine for cT2-T4aN0M0 Bladder Urothelial Cancer |
|
|
| Not yet recruiting | 4 | 65 | China | Tislelizumab+Gemcitabine+Cisplatin+Radical Cystectomy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ; Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, BeiGene (Beijing) Co., Ltd. | Bladder Urothelial Cancer | | | | |
ChiCTR2100054256: Clinical study of tislelizumab combined with gemcitabine and siggio in the first-line treatment of advanced pancreatic cancer |
|
|
| Recruiting | 4 | 30 | China | Tislelizumab in combination with gemcitabine and Sega | The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital) ; The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Beijing Medical Award Foundation | Advanced pancreatic cancer | | | | |
ChiCTR2200059848: A single-arm, prospective, Phase II clinical study of surufatinib in combination with tislelizumab in advanced colorectal cancer after third-line treatment failure |
|
|
| Not yet recruiting | 4 | 31 | China | Surufatinib+tislelizumab | Anhui Cancer Hospital ; Anhui Cancer Hospital, Self-financing | Colorectal cancer | | | | |
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. |
|
|
| Not yet recruiting | 4 | 312 | NA | HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06003673: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC |
|
|
| Recruiting | 4 | 20 | RoW | neoadjuvant therapy | First Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Resectable | 07/24 | 07/25 | | |
NCT06356675: A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy |
|
|
| Not yet recruiting | 4 | 33 | NA | Tislelizumab, Anlotinib | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Advanced NSCLC | 07/28 | 07/28 | | |
ChiCTR2300071481: The efficacy and safety of recombinant human adenovirus type 5 injection combined with tirelizumab and hepatic arterial infusion chemotherapy (HAIC) in the treatment of advanced primary hepatocellular carcinoma: a multicenter, prospective, one-arm study |
|
|
| Recruiting | 4 | 25 | China | Recombinant Human Adenovirus Type 5 Injection+Tislelizumab Injection +HAIC | Zhongda Hospital Southeast University ; Zhongda Hospital Southeast University, Beijing Health Promotion Association | Advanced primary hepatocellular carcinoma | | | | |
ChiCTR2100051747: The clinical study of Gegen Qinlian Decoction combined with immunotherapy and chemotherapy in treating lung squamous cell carcinoma(LUSC) |
|
|
| Not yet recruiting | 4 | 27 | China | PD-1 monoclonal antibody (Tislelizumab injection), platinum-containing dual-drug treatment and GQT (Gegen Qinlian tablet) | China-Japan Friendship Hospital ; China-Japan Friendship Hospital, BeiGene Biological Technology Co., Ltd | Lung squamous cell carcinoma | | | | |
NCT05580354: Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Not yet recruiting | 4 | 42 | RoW | BCG combined with Tislelizumab | Ruijin Hospital | Non-muscle-invasive Bladder Cancer | 10/24 | 05/25 | | |
ChiCTR2200062653: Clinical study of transformation treatment of tislelizumab combined with albumin paclitaxel and S-1 in patients with unresectable locally advanced and metastatic gastric cancer |
|
|
| Not yet recruiting | 4 | 121 | China | Tislelizumab combined with albumin paclitaxel and S-1 ;Tislelizumab combined with albumin paclitaxel and S-1 | The First Affiliated Hospital of Zhejiang University ; The First Affiliated Hospital of Zhejiang University, Fujian Province Medical Volunteer Association | Gastric cancer | | | | |
NCT05861635: The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression |
|
|
| Recruiting | 4 | 42 | RoW | Disitamab Vedotin combined with Tislelizumab | Wuhan Union Hospital, China | Breast Cancer, Neoadjuvant Therapy | 02/25 | 02/26 | | |
ChiCTR2200058342: A prospective phase II single-arm clinical study on the efficacy and safety of tislelizumab combined with induction chemotherapy + concurrent chemoradiotherapy + maintenance therapy in patients with stage III unresectable non-small cell lung cancer (NSCLC |
|
|
| Recruiting | 4 | 30 | China | Baizean (tislelizumab) - BeiGene, Novartis | Xiamen Humanity Hospital | Lung Cancer;Oncology | | | | |
ChiCTR2000032856: Efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer |
|
|
| Recruiting | 4 | 60 | China | 1. Tislelizumab 200mg, IV, 1 day before radiotherapy, q3w Until the disease progresses / or lasts for 1 year; 2. concurrent chemoradiotherapy. | Suzhou Municipal Hospital ; Suzhou Municipal Hospital, Sponsorship | Locally advanced cervical cancer | | | | |
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement |
|
|
| Not yet recruiting | 4 | 20 | | None | The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation | diffuse large B-cell lymphoma with secondary CNS involvement | | | | |
ChiCTR2200066771: Efficacy and adverse reactions of radiotherapy combined with immunotherapy and chemotherapy in advanced non-small cell lung cancer: a prospective, non-randomized, concurrent, controlled clinical study |
|
|
| Not yet recruiting | 4 | 165 | China | Radiotherapy+Tislelizumab+Paclitaxel liposome+Cisplatin ;radiotherapy+Tislelizumab+Pemetrexed+Cisplatin ;Tislelizumab+Paclitaxel liposome+Cisplatin ;Tislelizumab+Pemetrexed+Cisplatin | Yiyang Center Hospital ; Yiyang Center Hospital, Chen Xiaoping Foundation、Scientific research Project of Hunan Provincial Health Commission、Hospital self-raised | Non-small Cell Lung Cancer | | | | |
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | 1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd. | advanced intrahepatic cholangiocarcinoma | | | | |
ChiCTR2200059190: A multicenter, prospective, one-arm, real-world study of Tirelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 4 | 200 | China | Tislelizumab Injection | Qilu Hospital of Shandong University ; Qilu Hospital of Shandong University, Shandong University Transverse Fund | Esophageal Squamous Cell Carcinoma | | | | |
| Not yet recruiting | 4 | 41 | China | Tislelizumab combined with gemcitabine and cisplatin | Army Medical Center ; Army Medical Center, No | Bladder Cancer | | | | |
| Recruiting | 4 | 56 | | High-dose irradiation plus low-dose radiatlion combined with tislelizumab and lenvatinib | Pingxiang People's Hospital; Pingxiang People's Hospital, Pingxiang People's Hospital | hepatocellular carcinoma | | | | |
ChiCTR2300067495: Chemotherapy combined with Tislelizumab in fertility-preserving treatment of cervical cancer——a Phase II prospective, single arm clinical study |
|
|
| Recruiting | 4 | 10 | China | chemotherapy combined with Tislelizumab | Liaoning Cancer Hospital & Institute ; Liaoning Cancer Hospital & Institute, Hospital finance funding | Cervical Cancer | | | | |
